Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Menveo Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The growth witnessed during the historic period can be ascribed to the broadening of national immunization programs, past outbreaks of meningococcal disease, improvements in conjugate vaccine technology, heightened awareness regarding vaccine-preventable illnesses, and international vaccination campaigns.
The expansion during the projected timeframe can be linked to heightened investments in novel vaccine development, an intensified focus on preventing disease outbreaks, the broadened reach of immunization for adults and adolescents, the escalating need for travel-related vaccinations, and the reinforcement of public health infrastructure.
Significant trends expected in the forecast period involve the increasing uptake of conjugate vaccines, a greater emphasis on preventive immunization initiatives, a rising demand for vaccinations for adolescents and travelers, the expansion of multivalent vaccine coverage, and an enhanced focus on public health preparedness.
Get A Free Sample Report With In-Depth Market Insights:
Menveo Market Development Factors: What’s Supporting Demand?
The rising incidence of meningitis is anticipated to fuel the expansion of the menveo market in the coming years. This condition involves the inflammation of the brain and spinal cord’s protective membranes, frequently caused by viral, bacterial, or fungal agents. The growing occurrence of meningitis is largely due to factors like increased global travel and compromised immune systems, both of which elevate the likelihood of disease spread. Menveo contributes to public health initiatives by offering defense against various strains of Neisseria meningitidis, facilitating prompt prevention, curbing the spread of the disease, and alleviating the impact of invasive meningococcal infections. For instance, in October 2025, according to the UK Health Security Agency, a UK-based government agency, a total of 378 invasive meningococcal disease (IMD) cases were confirmed in 2024–25. Consequently, the escalating prevalence of meningitis is a key driver for the menveo market’s expansion.
Menveo Market Segment Analysis Spotlighting Growth Areas
The menveo market covered in this report is segmented –
1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine
2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination
3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults
4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities
Menveo Market Transformation Trends: What Innovations Are Driving Change?
A significant development in the menveo market focuses on creating advanced vaccine formulations, particularly single-vial, fully liquid types, to boost convenience, improve stability, and streamline administration. These single-vial, fully liquid formulations are pharmaceutical products that come pre-mixed and packaged in a single vial, with their active ingredients already dissolved in liquid, ready for immediate use. An illustration of this is when GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical industry company, secured approval from the European Commission (EC) in November 2024 for a new presentation of its meningococcal vaccine, Menveo. This approval is for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is currently licensed for individuals aged two years and older, adolescents, and adults. Key aspects of this vaccine’s approval include its authorization for active immunization within the European Union for children from two years of age, adolescents, and adults, notably featuring a novel single-vial, fully liquid presentation that eliminates the requirement for reconstitution before use.
Menveo Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc
View The Full Menveo Market Report:
Menveo Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
